Dysregulation of cholesterol balance contributes significantly to coronary heart disease (CHD), the leading cause of death in the United States. Molecular mechanisms regulating the transport of cholesterol into and out of the body have been well defined. It is generally accepted that cholesterol enters the body via intestinal absorption or endogenous synthesis, and is excreted out of the body via a hepatobiliary route, either as free sterol or following hepatic conversion to bile acids. Although it is believed that the hepatobiliary route is the major pathway for fecal cholesterol excretion in humans, we have recently found that fecal sterol loss is normal in mice unable to secrete cholesterol into bile. Furthermore, we have demonstrated that nascent liver-derived lipoproteins can deliver cholesterol to the intestine, indicating the presence of a non-biliary plasma-based route for fecal sterol loss. Our findings, along with others, suggest that the intestine may play an important role in the direct elimination of cholesterol. The objective of this work is to understand the molecular mechanisms regulating non-biliary fecal sterol loss through the intestine, a poorly understood pathway that may play a quantitatively important role in whole body cholesterol balance. During the mentored phase of this project, we propose to: 1) quantify biliary and non-biliary contributions to fecal cholesterol loss using surgical and genetic models of biliary insufficiency, and 2) determine whether plasma lipoprotein-mediated delivery of cholesterol to the intestine depends on the presence of apolipoprotein E. During the independent research phase, we propose to: 3) identify the carrier(s) responsible for cholesterol transport across the basolateral membrane of the enterocyte, and 4) identify the carrier(s) responsible for apical cholesterol transport into the small intestine lumen. Data obtained from these studies are expected to define molecular mechanisms regulating non-biliary fecal sterol loss, an obvious gap in the current knowledge base. By elucidating the molecular mechanisms regulating the excretory function of the small intestine, these studies may lead to the development of novel therapeutic approaches for modulating cholesterol balance in humans.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Career Transition Award (K99)
Project #
5K99HL096166-02
Application #
7790528
Study Section
Special Emphasis Panel (ZHL1-CSR-Z (F2))
Program Officer
Commarato, Michael
Project Start
2009-04-01
Project End
2011-03-31
Budget Start
2010-04-01
Budget End
2011-03-31
Support Year
2
Fiscal Year
2010
Total Cost
$90,000
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Pathology
Type
Schools of Medicine
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Lord, Caleb C; Ferguson, Daniel; Thomas, Gwynneth et al. (2016) Regulation of Hepatic Triacylglycerol Metabolism by CGI-58 Does Not Require ATGL Co-activation. Cell Rep 16:939-949
Marshall, Stephanie M; Gromovsky, Anthony D; Kelley, Kathryn L et al. (2014) Acute sterol o-acyltransferase 2 (SOAT2) knockdown rapidly mobilizes hepatic cholesterol for fecal excretion. PLoS One 9:e98953
Marshall, Stephanie M; Kelley, Kathryn L; Davis, Matthew A et al. (2014) Reduction of VLDL secretion decreases cholesterol excretion in niemann-pick C1-like 1 hepatic transgenic mice. PLoS One 9:e84418
Saddar, Sonika; Carriere, VĂ©ronique; Lee, Wan-Ru et al. (2013) Scavenger receptor class B type I is a plasma membrane cholesterol sensor. Circ Res 112:140-51
Bura, Kanwardeep S; Lord, Caleb; Marshall, Stephanie et al. (2013) Intestinal SR-BI does not impact cholesterol absorption or transintestinal cholesterol efflux in mice. J Lipid Res 54:1567-77
Lord, Caleb C; Betters, Jenna L; Ivanova, Pavlina T et al. (2012) CGI-58/ABHD5-derived signaling lipids regulate systemic inflammation and insulin action. Diabetes 61:355-63
Temel, Ryan E; Brown, J Mark (2012) Biliary and nonbiliary contributions to reverse cholesterol transport. Curr Opin Lipidol 23:85-90
Temel, Ryan E; Sawyer, Janet K; Yu, Liqing et al. (2010) Biliary sterol secretion is not required for macrophage reverse cholesterol transport. Cell Metab 12:96-102
Brown, J Mark; Rudel, Lawrence L (2010) Stearoyl-coenzyme A desaturase 1 inhibition and the metabolic syndrome: considerations for future drug discovery. Curr Opin Lipidol 21:192-7
Brown, J Mark; Chung, Soonkyu; Sawyer, Janet K et al. (2010) Combined therapy of dietary fish oil and stearoyl-CoA desaturase 1 inhibition prevents the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 30:24-30

Showing the most recent 10 out of 16 publications